Form 4: Lexaria Bioscience Corp. Director Nicholas Baxter Reports Transaction
SEC Form 4
Director Nicholas Baxter reports the disposition of 11,000 common shares and acquisition of 11,000 stock options in Lexaria Bioscience Corp.
Summary
- On May 15, 2025, Nicholas Baxter, a director of Lexaria Bioscience Corp., reported a transaction involving the company's securities.
- Baxter disposed of 11,000 common shares.
- Baxter acquired 11,000 stock options with an exercise price of $1.04, exercisable from May 15, 2025, and expiring on May 15, 2030.
- Following the reported transaction, Baxter directly owns 63,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a neutral report of a transaction. There is no positive or negative sentiment associated with the filing itself.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders, as it reflects an insider's trading activity.
Key Dates
| Date | Description |
|---|---|
| 04/26/2021 | Date exercisable for 1,500 common shares via stock options. |
| 04/26/2026 | Expiration date for 1,500 common shares via stock options. |
| 06/08/2021 | Date exercisable for 5,000 common shares via stock options. |
| 06/08/2026 | Expiration date for 5,000 common shares via stock options. |
| 09/01/2021 | Date exercisable for 1,900 common shares via stock options. |
| 09/01/2026 | Expiration date for 1,900 common shares via stock options. |
| 03/08/2022 | Date exercisable for 3,400 common shares via stock options. |
| 03/08/2027 | Expiration date for 3,400 common shares via stock options. |
| 10/12/2022 | Date exercisable for 18,200 common shares via stock options. |
| 10/12/2027 | Expiration date for 18,200 common shares via stock options. |
| 07/25/2023 | Date exercisable for 5,000 common shares via stock options. |
| 07/25/2028 | Expiration date for 5,000 common shares via stock options. |
| 04/26/2024 | Date exercisable for 5,000 common shares via stock options. |
| 04/26/2029 | Expiration date for 5,000 common shares via stock options. |
| 07/26/2024 | Date exercisable for 12,000 common shares via stock options. |
| 07/26/2029 | Expiration date for 12,000 common shares via stock options. |
| 05/15/2025 | Date of transaction: disposition of 11,000 common shares and acquisition of 11,000 stock options. |
| 05/15/2025 | Date exercisable for 11,000 common shares via stock options. |
| 05/15/2030 | Expiration date for 11,000 common shares via stock options. |
| 05/16/2025 | Date of signature. |
Keywords
Form 4, Nicholas Baxter, Lexaria Bioscience Corp., Director, Stock Options, Common Shares, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.